How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cancer Early Detection Market
- By Technology: Biopsy-based Detection, Blood-based Biomarker Testing, Imaging Techniques, Molecular Diagnostics, Genomic Sequencing
- By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer
- By End User: Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers, Cancer Research Institutes, Home Care Settings
- By Sample Type: Tissue Samples, Blood Samples, Urine Samples, Saliva Samples, Stool Samples
- By Methodology: Liquid Biopsy, Tissue Biopsy, Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction (PCR)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Biopsy-based Detection leads By Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 307 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Cancer Early Detection Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →F. Hoffmann-La Roche AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Becton Dickinson and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Guardant Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Exact Sciences Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Illumina Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Biocept Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Myriad Genetics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Natera Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Quest Diagnostics Incorporated
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Laboratory Corporation of America Holdings (LabCorp)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Hologic
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Biopsy-based Detection43.3
- Blood-based Biomarker Testing10.4
- Imaging Techniques19.7
- Molecular Diagnostics15.7
- Genomic Sequencing11.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diagnostics12.1
- Abbott Laboratories25.4
- F. Hoffmann-La Roche AG3.9
- Thermo Fisher Scientific12.0
- Siemens Healthineers6.2
- Becton Dickinson and Company12.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe23.8
- Asia Pacific20.8
- Latin America11.9
- Middle East and Africa9.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diagnostics | 83 | 77 | 96 | 80 | 95 | 88 | 87 |
| Abbott Laboratories | 74 | 93 | 78 | 73 | 71 | 70 | 77 |
| F. Hoffmann-La Roche AG | 75 | 74 | 67 | 82 | 72 | 87 | 76 |
| Thermo Fisher Scientific | 62 | 59 | 74 | 58 | 57 | 71 | 64 |
| Siemens Healthineers | 69 | 57 | 76 | 70 | 59 | 73 | 67 |
| Becton Dickinson and Company | 50 | 48 | 58 | 61 | 55 | 48 | 53 |
| Guardant Health | 58 | 50 | 56 | 58 | 46 | 55 | 54 |
| Exact Sciences Corporation | 59 | 57 | 46 | 40 | 49 | 43 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diagnostics
- Abbott Laboratories
- F. Hoffmann-La Roche AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diagnostics | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Abbott Laboratories | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| F. Hoffmann-La Roche AG | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Thermo Fisher Scientific | ◐ | ◐ | ✓ | − | ◐ | ✓ |
| Siemens Healthineers | ◐ | ◐ | ◐ | − | − | ◐ |
| Becton Dickinson and Company | − | ◐ | ◐ | − | ◐ | ◐ |
| Guardant Health | ◐ | ◐ | ◐ | − | − | − |
| Exact Sciences Corporation | ◐ | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Challenger3
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Technology in North America, then scale across Cancer Early Detection Market — a $495M beachhead inside a $6.82B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Biopsy-based Detection
Best fit — highest urgency & budget in Technology.
Blood-based Biomarker Testing
Strong fit — clear ROI and a fast path to value.
Imaging Techniques
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cancer Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cancer Early Detection Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Cancer Early Detection Market is a high-growth opportunity — $10.0B by 2033, compounding at 11.6%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.6% CAGR
Demand compounds through 2033, outpacing GDP across Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cancer Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Cancer Early Detection Market — a $4.44B market by 2033. Plan: grow share from 7.9% to 12.6%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 12.6% | Behind |
| Revenue | $323M | $560M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.4% | 45.9% | Behind |
| Customer retention | 89.0% | 95.4% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Cancer Type capability
A defensible second engine — invest in Cancer Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cancer Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $70M capacity & capability investment
- Greenlight bolt-on M&A in Cancer Type
- Authorise North America expansion plan
- Fund R&D program for Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Sales deck · value proposition
Win the Cancer Early Detection Market conversation — a $1.91B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology
Goal Grow share in Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cancer Early Detection Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Cancer Early Detection Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Cancer Early Detection and Screening Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCancer Early Detection and Diagnosis Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCancer Drug based on PARP Inhibitor Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportDissolution Testers Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCancer Drug based on CAR-T Market
Cancer Drug based on CAR-T Market is valued at USD 13.42 Billion in 2025 and is expected to rea…
$13.4B market · 2025 base year
View reportCancer Diagnostic Test Kits Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportCancer Diagnostics Service Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportCancer Diagnostics Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCancer Cryosurgery Instruments and Accessories Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportCancer Cell Media Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportCancer Cell Biopsy Service Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportCancer Cell Analysis Market
Cancer Cell Analysis Market is valued at USD 5.12 Billion in 2025 and is expected to reach USD …
$5.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy